Connect with us

Medical Devices

AirPhysio Natural Lung-Expansion OPEP Device For Asthma Symptom Relief Updated

Published

on

Tweed Heads, Australia, Sept. 15, 2021 (GLOBE NEWSWIRE) —

AirPhysio aids in mucus clearance and lung expansion and is suited to 99% of those with respiratory issues, including acute and severe conditions. The relaunched product is drug-free and can be used as a treatment and a preventative measure for asthma, atelectasis bronchiectasis, COPD, emphysema, chronic bronchitis, and cystic fibrosis.

More information can be found at:https://media.lifewellnesshealthcare.com/3tf7FxK

Data shows that respiratory conditions are responsible for numerous hospitalizations and mortalities across the globe, with four million chronic obstructive pulmonary disease (COPD) sufferers dying each year. Life Wellness Healthcare strives to reduce complications and risks from respiratory conditions with its rereleased product.

The team explains that one in 13 Americans suffers from asthma, including 7% of children and 8% of adults. It is a condition that causes swelling within the airways which, in turn, reduces the amount of oxygen reaching the lungs. Symptoms range from coughing to tightness of the chest and trouble breathing.

Life Wellness Healthcare has developed a reputation for improving lung health and capacity, which is made possible through products such as the AirPhysio. The internationally award-winning product can assist with better breathing for adults, children, the elderly, and smokers. The lung-cleaning device is also useful for divers, athletes, singers, and musicians who require healthy lungs.

The device has an oscillating positive expiratory pressure feature, which loosens the bond of the mucus in the airways. In addition, this positive pressure then helps to target the mucus and push it up and out of the body, aiding the natural mucus-clearing process.

Most users will only need to use the product for five minutes, one to three times per day, and there are also extra, disposable filters available. These filters are not required for the device to operate, but help to catch 99.9% of viruses and bacteria.

A recent customer said: “This is a simple yet very effective device. I’ve suffered from lung challenges for many years, and I instantly felt an improvement the first day I started using this. Consistency is key, but it works.”

Interested parties can learn more at:https://media.lifewellnesshealthcare.com/3tf7FxK

Website: https://lifewellnesshealthcare.com/


Name: Matthew Fraser
Email: matthew@fraserimporting.com
Organization: Life Wellness Healthcare
Address: PO BOX 6662, Tweed Heads, NSW 2486, Australia
Phone: +61-7-3608-5683

Primary Logo

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/airphysio-natural-lung-expansion-opep-device-for-asthma-symptom-relief-updated-/?s=93

Medical Devices

Paragon 28, Inc. Announces Pricing of Initial Public Offering

Published

on

Oct. 15, 2021 02:35 UTC

ENGLEWOOD, Colo.–(BUSINESS WIRE)– Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by PARAGON. PARAGON’s common stock is expected to begin trading on the New York Stock Exchange on October 15, 2021, under the ticker symbol “FNA.” The offering is expected to close on October 19, 2021, subject to the satisfaction of customary closing conditions. In addition, PARAGON has granted the underwriters a 30-day option to purchase up to an additional 1,171,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

BofA Securities and Piper Sandler are acting as joint lead book-running managers for the offering. Canaccord Genuity is acting as a lead manager. JMP Securities and Needham & Company are acting as co-managers.

A registration statement relating to the shares being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on October 14, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained from: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e-mail at prospectus@psc.com, or by phone at (800) 747-3924.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211014006180/en/

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/paragon-28-inc-announces-pricing-of-initial-public-offering/?s=93

Continue Reading

Medical Devices

Apollo Endosurgery Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

Published

on

AUSTIN, TX / ACCESSWIRE / October 15, 2021 / Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the closing of its previously announced underwritten public offering. Apollo sold 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $7.75 per share for gross proceeds of approximately $75 million, before deducting underwriting discounts and commissions and offering expenses.

Piper Sandler, Cowen and Stifel acted as the joint book-running managers for the proposed offering. Craig-Hallum and Lake Street acted as co-managers for the offering.

The offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, filed by Apollo with the Securities and Exchange Commission (the “SEC”), which was declared effective by the SEC on May 19, 2021. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus related to the offering may be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on development of next-generation, less invasive devices to advance therapeutic endoscopy designed to treat a variety of gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. Apollo’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products are offered in over 75 countries today and include the X-Tack® Endoscopic HeliX Tacking System, the OverStitch® Endoscopic Suturing System, the OverStitch Sx® Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

CONTACT:

Apollo Endosurgery, Inc.
Jeff Black, 512-279-5126
investor-relations@apolloendo.com

Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com

SOURCE: Apollo Endosurgery, Inc.

View source version on accesswire.com:
https://www.accesswire.com/668389/Apollo-Endosurgery-Announces-Closing-of-Public-Offering-and-Exercise-in-Full-of-Option-to-Purchase-Additional-Shares

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/apollo-endosurgery-announces-closing-of-public-offering-and-exercise-in-full-of-option-to-purchase-additional-shares/?s=93

Continue Reading

Medical Devices

Neuvotion Secures over $1M in Seed Funding to Commercialize Neurostimulation Technology

Published

on

 

DARIEN, Conn., Oct. 14, 2021 /PRNewswire/ — Neuvotion, Inc., an early-stage medical device company developing neurostimulation products for the rehabilitation and physical therapy markets, today announced that it has received over $1M in seed funding.  The Long Island Angel Network, an organized group of individual angel investors based on Long Island, and the Good Shepherd Rehabilitation Network,  a nationally recognized rehabilitation leader, have provided the company with its first equity investment. This seed funding will be used by Neuvotion to expand its team, conduct a multi-site clinical study, and seek FDA clearance for its initial product.

Further, Neuvotion secured exclusive worldwide rights to transformative technology developed by its founder, Chad Bouton, who is a professor at the Feinstein Institutes for Medical Research at Northwell Health. “I am inspired by the prospect of helping the millions of patients who have experienced a stroke, traumatic injury, or are living with movement impairment, to reach their goals,” said Chad Bouton, Founder & CEO of Neuvotion. “We are working to commercialize NeuStim™ and other technologies so they can be used in clinical practice, and ultimately in the home to increase quality of life and independence.”

“We have been very impressed with Professor Bouton’s work and are pleased to support its commercialization through our seed investment in Neuvotion,” said Steve Winick, Managing Director of Topspin Fund and member of the Long Island Angel Network. “As a leading provider of rehabilitation services, we see tremendous clinical potential for Neuvotion’s NeuStim technology,” added Michael Spigel, PT, MHA, President & CEO of Good Shepherd Rehabilitation Network. “We look forward to serving as a foundational research partner in Neuvotion’s upcoming multi-site clinical study. We feel strongly that this technology can help transform lives for people with spinal cord injuries, strokes and other neurological conditions.”

About Neuvotion
Neuvotion (www.neuvotion-inc.com) is an early-stage medical device company developing solutions for facilitating and restoring movement to the millions of patients experiencing impairment from stroke, traumatic injury, and other conditions. Its NeuStim™ technology combines highly targeted neurostimulation and artificial intelligence to make physical and occupational therapy more effective and efficient. Neuvotion is planning a multi-site clinical study to begin next year.

About Long Island Angel Network
The Long Island Angel Network (LIAN; http://www.liangels.net/) is a New York not-for-profit corporation consisting of individual angel investors interested in financing early-stage and emerging growth companies, primarily in technology- and innovation-focused areas. LIAN screeners endeavor to select companies for presentation that they judge likely to be of the greatest interest to members, but the Network does not make investment recommendations; investors’ decisions are made individually. LIAN’s goal is to back our region’s most exciting, promising early-stage growth companies.

About Good Shepherd Rehabilitation Network
Good Shepherd Rehabilitation Network (https://www.goodshepherdrehab.org/), a nationally recognized, not-for-profit rehabilitation leader with more than 70 locations throughout Pennsylvania and New Jersey, is committed to transforming lives through expertise, innovation, and compassion. Good Shepherd provides an exceptional patient experience for all ages and stages by developing leading-edge solutions, often for complex medical situations; serving as a test site for the newest rehabilitation technologies; and inspiring hope in all we do. Headquartered in Allentown, Pennsylvania, Good Shepherd also partners with Penn Medicine to provide rehabilitation and specialty services in the greater Philadelphia area and New Jersey through Good Shepherd Penn Partners.

If you would like more information about this topic, please call Travis Millman at +1 (917) 496-3663, or email info@neuvotion-inc.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neuvotion-secures-over-1m-in-seed-funding-to-commercialize-neurostimulation-technology-301399861.html

SOURCE Neuvotion

 

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/neuvotion-secures-over-1m-in-seed-funding-to-commercialize-neurostimulation-technology/?s=93

Continue Reading

Medical Devices

FEops HEARTguide Authorized by FDA for Unprecedented LAAo Planning Capabilities

Published

on

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005139/en/

“The pre-operative insight provided by FEops HEARTguide™ is powerful and can help me to optimize decision making for selecting optimal device size and position,” said Dr Jacqueline Saw, Vancouver General Hospital, Canada. “FEops HEARTguide™ is an intuitive platform I can use to discuss cases with the entire heart team to streamline my pre-op planning workflow.”

“FDA authorization of FEops HEARTguide™ is a significant milestone as this is the first Interventional Cardiovascular Implant Simulation Software Device cleared on the US market,” said Peter Mortier, PhD, co-founder and CTO of FEops. “Research on this technology began more than 10 years ago. We have continued to develop it with the goal of helping healthcare professionals identify the most appropriate treatment strategy for each patient precisely, safely and efficiently. This De Novo clearance is only a first step, and we are already preparing for FDA 510(k) submissions for FEops HEARTguide™ LAAo workflow with Abbott’s Amplatzer™ Amulet™ device and Boston Scientific’s WATCHMAN FLX™ device.”

*The Owner/Operator Number for this Registration is: 10082838 and the listing number: DEN200030.

FEops HEARTguide™ is a one-in-its-kind procedure planning platform for structural heart interventions that provides physicians with unique insights to evaluate device sizing and positioning pre-operatively. The platform uses digital twin technology based on patient-specific virtual replicas of the heart. Besides the recent FDA clearance to enter the US market with its LAAo workflow with WATCHMAN™, FEops HEARTguide™ is also commercially available in the European Union, UK, Canada and Australia for its TAVI and LAAo workflows.

About FEops HEARTguide™

FEops HEARTguideTM cloud-based procedure planning environment uses digital twin technology to provide clinicians and medical device manufacturers with first-ever insights into the interaction between transcatheter structural heart devices and specific patient anatomy – pre-operatively. Additionally, this includes also a range of quality controlled, validated and AI-enabled** anatomical analyses. Such insights have the power to help ultimately to improve clinical outcomes in real-world hospital settings, as well as to accelerate research and development of novel device-based solutions.

** Currently available only in the European Union, UK, Canada and Australia for its TAVI and LAAo workflows.

About FEops

Privately held FEops, headquartered in Gent, Belgium, is a digital health player offering cloud-based procedure planning solutions in the structural heart space combining digital twin and AI technologies. In September 2017, FEops announced that it closed a 6 million euros financing, led by Valiance, and joined by existing investors Capricorn Partners and PMV. In December 2019, FEops has been awarded a grant of Euro 3.2 million from the European Innovation Council (EIC) accelerator programme.

www.feops.com

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/feops-heartguide-authorized-by-fda-for-unprecedented-laao-planning-capabilities/?s=93

Continue Reading
Esports4 days ago

Ill Gotten Gain New World: How to Obtain the Earring

Esports2 days ago

The best teams in Hearthstone Mercenaries

Esports4 days ago

What is Bullet Stumble in Back 4 Blood?

Esports5 days ago

How to Unlock All Characters in Demon Slayer: The Hinokami Chronicles

Esports4 days ago

How to Increase Your Corporate Level in NBA 2K22 MyCareer

Esports5 days ago

Blizzard Removes “Greenskin” References In World Of Warcraft

Energy4 days ago

Dover Announces Acquisition Of LIQAL B.V., A Leading Provider Of LNG And Hydrogen Fueling Solutions

Energy5 days ago

Quanta Services Completes the Previously Announced Acquisition of Blattner

Energy5 days ago

USD 1.47 bn Growth in Dies and Molds Market In India from 2021 to 2025|Alfa Plast Mould and Classic Die Tools emerge as Key Contributors|17000+ Technavio Reports

Esports2 days ago

How Many Chapters are in the Demon Slayer Game?

Blockchain5 days ago

Choosing Flexible CRM Integration Against In-House Confusion

Cleantech4 days ago

U.S. Secretary Haaland Outlines Ambitious Offshore Wind Leasing Strategy

Cannabis5 days ago

KETAMINE: What Is It?

Esports4 days ago

What is the Faction Reputation cap in New World?

Blockchain5 days ago

TRON and APENFT partner with Decentral Games to take GameFi to the next level

Esports4 days ago

Ricochet Unable to Target Cronus and Controller Hacks, Activision Working on Fix

Energy4 days ago

Sigma Lithium Says Technology Will Be Key To Make Lithium Greener And Cheaper At Financial Times Live Commodities Summit

Aviation4 days ago

Ottawa eyes charging airport security with vaccine verification for travellers

Energy5 days ago

Navigator Approved To Proceed With Development and Construction of Heartland Greenway System in Midwest

Energy5 days ago

Duke Energy Foundation awards $190,000 in grants to support environmental initiatives in Indiana communities

Trending